ZEB2 3'UTR Construct (1.4 Kb UTR, contains miR_200 family sites) miR_Selection lentivector
- Known as:
- ZEB2 3'UTR Construct (1.4 Kb UTR, contains miR_200 family sites) miR_Selection lentivector
- Catalog number:
- MS433A-1
- Product Quantity:
- 10 ug
- Category:
- -
- Supplier:
- SBI
- Gene target:
- ZEB2 3'UTR Construct (1.4 UTR contains miR_200 family sites) miR_Selection lentivector
Related genes to: ZEB2 3'UTR Construct (1.4 Kb UTR, contains miR_200 family sites) miR_Selection lentivector
- Gene:
- A4GALT NIH gene
- Name:
- alpha 1,4-galactosyltransferase (P blood group)
- Previous symbol:
- P1
- Synonyms:
- A14GALT, Gb3S, P(k)
- Chromosome:
- 22q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 2002-02-06
- Date modifiied:
- 2019-04-23
- Gene:
- ABCA11P NIH gene
- Name:
- ATP binding cassette subfamily A member 11, pseudogene
- Previous symbol:
- ABCA11
- Synonyms:
- EST1133530, FLJ14297
- Chromosome:
- 4p16.3
- Locus Type:
- pseudogene
- Date approved:
- 1999-06-11
- Date modifiied:
- 2015-11-13
- Gene:
- ABCB7 NIH gene
- Name:
- ATP binding cassette subfamily B member 7
- Previous symbol:
- ABC7
- Synonyms:
- EST140535, Atm1p, ASAT
- Chromosome:
- Xq13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1997-09-12
- Date modifiied:
- 2019-04-23
- Gene:
- ABCC5 NIH gene
- Name:
- ATP binding cassette subfamily C member 5
- Previous symbol:
- -
- Synonyms:
- MRP5, SMRP, EST277145, MOAT-C
- Chromosome:
- 3q27.1
- Locus Type:
- gene with protein product
- Date approved:
- 1999-10-26
- Date modifiied:
- 2016-10-05
- Gene:
- ABCF1 NIH gene
- Name:
- ATP binding cassette subfamily F member 1
- Previous symbol:
- ABC50
- Synonyms:
- EST123147
- Chromosome:
- 6p21.33
- Locus Type:
- gene with protein product
- Date approved:
- 1998-04-07
- Date modifiied:
- 2015-11-13
Related products to: ZEB2 3'UTR Construct (1.4 Kb UTR, contains miR_200 family sites) miR_Selection lentivector
'VX-200 Vortex Mixer Optional head attachment for 1 microplate or 64 x 0.2 ml tubes or 8 x 0.2 ml tube strips'VX-200 Vortex Mixer Optional head attachment for 12 x 1.5/2.0 ml tubes, held horizontally'VX-200 Vortex Mixer Optional head attachment for 2 x 50 ml tubes, held horizontally'VX-200 Vortex Mixer Optional head attachment for 24 x 1.5/2.0 ml tubes, 24 x 0.5 ml tubes and 32 x 0.2 ml tubes (or 4 tube strips)'VX-200 Vortex Mixer Optional head attachment for 4 x 15 ml tubes, held horizontally'VX-200 Vortex Mixer Optional head attachment for 6 x 50 ml tubes'VX-200 Vortex Mixer Optional head attachment for 8 x 15 ml and 8 x 12/13 mm diameter tubes(+__)_Camphene contains ca 20% rich cy(-)-(2R,5R)-2,5-Dimethylpyrrolidine, Hydrochloride, 90% (contains meso-isomer) C6H14ClN CAS: 70144-18-2 (-)-(2R,5R)-2,5-Dimethylpyrrolidine, Hydrochloride, 90% (contains meso-isomer) CAS: 70144-18-2 Formula: C6H14ClN(R)-Bicalutamide(Z)-4-Hydroxy-N-desmethyl Tamoxifen (contains up to 10% E isomer)
C25H27NO2 CAS: 112093-28-4(Z)-4-Hydroxy-N-desmethyl Tamoxifen (contains up to 10% E isomer)
CAS: 112093-28-4 Formula: C25H27NO2 *Lactobacillus Selection Agar Base USE For isolation and enumeration of Lactobacillus from foods.*Lactobacillus Selection Broth Base USE For the selective isolation,cultivation and enumeration of Lactobacilli from foods. Related articles to: ZEB2 3'UTR Construct (1.4 Kb UTR, contains miR_200 family sites) miR_Selection lentivector
- Long non-coding RNA (lncRNA) is aberrantly expressed in a variety of tumor diseases. To date, its specific role in acute myeloid leukemia (AML) has not been fully elucidated. This study aims to evaluate the association between aberrant lncRNA expression and poor prognosis in AML patients, and to systematically assess the relationship between aberrant lncRNA expression and AML prognosis. - Source: PubMed
Publication date: 2025/02/04
Liu GuihongSun LiangliangLv PengQiao RongWang LihangJin Arong - - Source: PubMed
Publication date: 2024/02/23
- The objective of this study was to elucidate the expression of long non-coding RNA (lncRNA) in leiomyomas (Lyo) and paired myometrium (Myo) and explore the impact of race and MED12 mutation. Fold change analysis (Lyo/paired Myo) indicated the expression of 63 lncRNAs was significantly altered in the mutated group but not in the non-mutated Lyo. Additionally, 65 lncRNAs exhibited an over 1.5-fold change in the Black but not the White group. Fifteen differentially expressed lncRNAs identified with next-generation sequencing underwent qRT-PCR confirmation. Compared with Myo, the expression of , , , , , , , , , , , and was significantly higher, while the expression of , , and was significantly lower. Comparison of normal Myo with diseased Myo showed significant differences in the expression of several lncRNAs. Analysis based on race and Lyo MED12 mutation status indicated a significantly higher expression of , , , , and in Lyo from Black patients. The expression of , , , , , , , , , and was higher, while was significantly lower in the MED12-mutated group. These results indicate that Lyo are characterized by aberrant lncRNA expression, which is further impacted by race and Lyo MED12 mutation status. - Source: PubMed
Publication date: 2024/01/21
Chuang Tsai-DerTon NhuRysling ShawnBoos DrakeKhorram Omid - Genetic and/or epigenetic alterations in hematopoietic stem cells (HSCs) contribute to leukemia stem cell (LSC) formation. We aimed to identify alterations in the lncRNA expression profile signature of LSCs upon inhibition of PI3K/Akt/mTOR signaling, which provides selective advantages to LSCs. We also aimed to elucidate the potential interaction networks and functions of differentially expressed lncRNAs (DELs). We suppressed PI3K/Akt/mTOR signaling in LSC and HSC cell-lines by specific PI3K/mTOR dual-inhibitor (VS-5584) and confirmed the inhibition by antibody-array. We defined DELs by qRT-PCR. Increased , , , , , and decreased , , , , , and levels (|log2fold-change|>5) were strictly associated with PI3K/Akt/mTOR pathway inhibition in LSC. We performed analyses for DELs. was found to be specifically expressed in normal bone marrow and predominantly lower in leukemic cell-lines. Three sub-clusters were identified for DELs and they were associated with "abnormality of multiple cell lineages in the bone marrow." DELs were most highly enriched for "glucuronidation" Reactome pathway and "ascorbate and aldarate metabolism" and "inositol phosphate metabolism" KEGG pathways. Transcription factors, MBD4, NANOG, PAX6, RELA, CEBPB, and CEBPA were predicted to be associated with the DEL profile. was predicted to interact with CREB1, RARA, and PPARA. The possible DELs' targets were predicted to form six ontological groups, be highly enriched for phosphoprotein, and be involved in "PPAR signaling pathway" and "ChREBP regulation by carbohydrates and cAMP." These results will help to elucidate the roles of lncRNAs in the mechanisms that provide selective advantages to leukemia stem cells. - Source: PubMed
Publication date: 2023/07/20
Kayabasi CaglaGunduz Cumhur - Breast cancer is considered the most prevalent type of cancer in women and accounts for a high rate of death. A body of research has demonstrated that lncRNAs have a regulatory function in human diseases, especially cancers. ZEB2-AS1 is known as an oncogenic lncRNA in various types of cancers, and its deregulation may contribute to cancer development and progression. Therefore, we aimed to reveal the association of ZEB2-AS1 expression with epithelial-mesenchymal transition (EMT) markers, as a hallmark of cancer progression, in a clinical setting. - Source: PubMed
Publication date: 2023/04/23
Zarei MahboobehMalekzadeh KianooshOmidi MahmoudMousavi Pegah